Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248141 · ClinicalTrials.gov registry record
Understanding Hemophilia A and B Drug Dosage Administration Patterns
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 11
- Enrollment target
NCT03248141 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 11 participants.
The verdict
NCT03248141 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
Study Design A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings. 30 sites will enroll approximately 300 patients Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate. Physicians complete a retrospective chart review on each enrolled patient. Patients will complete a one-time study questionnaire.
Interventions
- DRUG Hemophilia B standard half-life
- DRUG Hemophilia B extended half-life
- DRUG Hemophilia A standard half-life
- DRUG Hemophilia A extended half-life
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-03-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248141
The ClinicalTrials.gov registry entry for NCT03248141 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Hemophilia B standard half-life is the first listed.
NCT03248141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03248141 about?
NCT03248141 is a clinical study titled "Understanding Hemophilia A and B Drug Dosage Administration Patterns". Study Design A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings. 30 sites will enroll approximately 300 patients Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate...
What is the current status of trial NCT03248141?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2017-09-01. Estimated completion is 2018-03-14.
What interventions are being tested in trial NCT03248141?
The interventions under investigation include: Hemophilia B standard half-life (DRUG), Hemophilia B extended half-life (DRUG), Hemophilia A standard half-life (DRUG), Hemophilia A extended half-life (DRUG).
Who is sponsoring clinical trial NCT03248141?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.